Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

Katrine R Schoennemann; Jon K Bjerregaard; Tine Hansen; Karin de Stricker; Morten F Gjerstorff; Helle A Jensen; Lene W Vestermark; Per Pfeiffer

doi:10.1007/s10120-011-0031-7

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

Katrine R Schoennemann, Jon K Bjerregaard, Tine Hansen, Karin de Stricker, Morten F Gjerstorff, Helle A Jensen, Lene W Vestermark, Per Pfeiffer

Center for Cancer Immune Therapy (CCIT), Department of Oncology, Copenhagen University Hospital , Herlev, Denmark.

18 Citationer (Scopus)

Abstract

Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by an expert panel appointed by the National Board of Health. This program has accelerated the introduction and implementation of new therapies in Denmark. Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC.

Originalsprog	Engelsk
Tidsskrift	Gastric Cancer
Vol/bind	14
Udgave nummer	3
Sider (fra-til)	219-25
Antal sider	7
ISSN	1436-3291
DOI	https://doi.org/10.1007/s10120-011-0031-7
Status	Udgivet - 2011

Adgang til dokumentet

10.1007/s10120-011-0031-7

Citationsformater

@article{0e4d3509652b47df86c4ec8c70adc083,

title = "Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum",

abstract = "Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by an expert panel appointed by the National Board of Health. This program has accelerated the introduction and implementation of new therapies in Denmark. Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Esophageal Neoplasms, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Salvage Therapy, Stomach Neoplasms, Survival Rate, Treatment Outcome",

author = "Schoennemann, {Katrine R} and Bjerregaard, {Jon K} and Tine Hansen and {de Stricker}, Karin and Gjerstorff, {Morten F} and Jensen, {Helle A} and Vestermark, {Lene W} and Per Pfeiffer",

year = "2011",

doi = "10.1007/s10120-011-0031-7",

language = "English",

volume = "14",

pages = "219--25",

journal = "Gastric Cancer",

issn = "1436-3291",

publisher = "Springer Japan KK",

number = "3",

}

TY - JOUR

T1 - Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

AU - Schoennemann, Katrine R

AU - Bjerregaard, Jon K

AU - Hansen, Tine

AU - de Stricker, Karin

AU - Gjerstorff, Morten F

AU - Jensen, Helle A

AU - Vestermark, Lene W

AU - Pfeiffer, Per

PY - 2011

Y1 - 2011

N2 - Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by an expert panel appointed by the National Board of Health. This program has accelerated the introduction and implementation of new therapies in Denmark. Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC.

AB - Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by an expert panel appointed by the National Board of Health. This program has accelerated the introduction and implementation of new therapies in Denmark. Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Camptothecin

KW - Esophageal Neoplasms

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Organoplatinum Compounds

KW - Salvage Therapy

KW - Stomach Neoplasms

KW - Survival Rate

KW - Treatment Outcome

U2 - 10.1007/s10120-011-0031-7

DO - 10.1007/s10120-011-0031-7

M3 - Journal article

C2 - 21409520

SN - 1436-3291

VL - 14

SP - 219

EP - 225

JO - Gastric Cancer

JF - Gastric Cancer

IS - 3

ER -

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater